- Home
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Team
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- TORRENT PHARMA
TORRENT PHARMA Share Price 
(TORR)
Here is the latest stock price and chart of Torrent Pharma. For more details, see the Torrent Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Oct 23, 2017 03:06:00 PM | ||
|---|---|---|---|
| Price (Rs)1,371.30 | Open (Rs) 1,362.00 | High (Rs) 1,411.45 | Low (Rs) 1,362.00 |
| % Change1.07 | Volume 18,215 | Value (Rs) 24,978,230 | 52-Week H/L 1,640.95 / 1,143.50 |
| Live NSE Quotes | Oct 23, 2017 3:09:58 PM | ||
|---|---|---|---|
| Price (Rs)1,373.40 | Open (Rs) 1,360.00 | High (Rs) 1,413.70 | Low (Rs) 1,360.00 |
| % Change0.80 | Volume 209,993 | Value (Rs) 292,673,544 | 52-Week H/L 1,639.95 / 1,141.95 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 49.04 | P/E Ratio (x) 27.96 | Market Cap (Rs m) 232,106.24 | P/BV (x) 6.85 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
Torrent Pharma Share Price Chart (Rs) - 1 Year 
Peer Group:
Quote & Graph- AARTI DRUGS
- ABBOTT INDIA
- AJANTA PHARMA
- ALEMBIC PHARMA
- AUROBINDO PHARMA
- BIOCON LTD
- CADILA HEALTHCARE
- CIPLA
- DIVIS LABORATORIES
- DR. REDDYS LAB
- GLENMARK PHARMA
- GSK PHARMA
- INDOCO REMEDIES
- IPCA LABS
- J.B.CHEMICALS
- LUPIN LTD
- MERCK LTD
- NATCO PHARMA
- NOVARTIS
- ORCHID PHARMA LTD
- PANACEA BIOTECH
- PFIZER
- PIRAMAL ENTERPRISES
- SANOFI INDIA
- STRIDES SHASUN LTD
- SUN PHARMA
- WOCKHARDT LTD.
- WYETH LTD
S&P BSE SENSEX
PERIOD - Advanced Charts new
|
| |
Today's Market
Sensex Pares Gains; Telecom Stocks Rally(01:30 pm)
After opening the day on a firm note, the Indian share markets pared its morning gains to trade flat. Sectoral indices are trading mixed, with stocks in the realty sector.
Related Views On News
Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)
Sep 22, 2017Muted growth in CRAMS segment continues to impact topline.
Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)
Aug 14, 2017A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)
Aug 14, 2017GST impact coupled with price erosion in US leads to lower profits for the quarter.
Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)
Aug 8, 2017Profits plunge due to higher raw material costs.
Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)
Jun 23, 2017Net Profit lower due to exceptional items in the previous year.
More Views on NewsMost Popular
Timeless Stocks on the Electric Car Assembly Line(The 5 Minute Wrapup)
Oct 10, 2017Are they on their way to create Coca Cola-like wealth?
Why Merger of Public Sector Banks Continues to Be a Bad Idea(Vivek Kaul's Diary)
Oct 10, 2017There is enough research evidence that suggests that most mergers don't work.
Electric Vehicles: The Final Piece of the Puzzle(Smart Contrarian)
Oct 16, 2017Just as there would be gainers from an electric vehicles boom, who possibly could be the biggest losers.
Mutual Funds Re-categorised... But What About Stocks?(Daily Profit Hunter)
Oct 11, 2017The market regulator can solve systemic issues but you must tackle the behavioral biases on your own.
Companies Are Wary of Borrowing(Chart Of The Day)
Oct 17, 2017How to profit from behavioral biases afflicting the industry.
More|
| |
TRACK TORRENT PHARMA
- Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON TORRENT PHARMA
TORRENT PHARMA - MYLAN COMPARISON
COMPARE TORRENT PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.